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Background/Aims: Although LIN28A is known to potentially 
play a role in the oncogenesis of various cancers, whether 
LIN28A expression is a predictor of poor prognosis in pa-
tients with gastric cancer has not been fully explored. We 
sought to evaluate clinicopathological characteristics accord-
ing to the expression of LIN28A in numerous gastric cancer 
tissue samples. Methods: LIN28A expression was evaluated 
by immunohistochemical (IHC) analysis of a tissue microar-
ray comprising 288 gastric cancer tissues and 288 adjacent 
normal tissues. Clinicopathological characteristics, including 
overall survival, were compared according to LIN28A expres-
sion. Results: The IHC staining score was lower for the can-
cer tissues than the normal tissues (p<0.001). However, no 
significant differences were observed in the clinicopathologi-
cal characteristics between the low and high LIN28A expres-
sion groups. In addition, the 5-year overall survival rate did 
not differ between the two groups: 75.3% (95% confidence 
interval [CI], 69.3% to 81.7%) versus 71.6% (95% CI, 63.3% 
to 80.9%) for low versus high expression, respectively. Con-
clusions: The expression of LIN28A did not appear to play 
a distinct role in predicting the clinicopathological charac-
teristics of patients with gastric cancer. In addition, LIN28A 
expression was not an independently associated factor for 
overall survival in patients with gastric cancer. (Gut Liver 
2016;10:714-718)
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INTRODUCTION
While the survival rates of patients with early gastric cancer 
have improved with the increase of earlier diagnoses in Korea 
and Japan due to the use of endoscopy screening,1-4 the long-
term oncologic outcomes of treatment in patients with advanced 
gastric cancer are still relatively poor.5,6 Although ongoing col-
laborative sequencing efforts have highlighted recurrent somatic 
genomic aberrations in gastric cancer, the outcomes of patients 
have not sufficiently improved.7 Better understanding of the 
molecular pathogenesis of gastric carcinogenesis may be needed 
for the advancement of gastric cancer treatments.
LIN28A is a highly conserved RNA-binding protein that was 
originally recognized as a key regulator of developmental tim-
ing in Caenorhabditis elegans.8 Recently, a study on LIN28A 
showed that it is overexpressed in various human cancers and 
functions as an oncogenes.9 p53 activates the expression of 
miR-34a and miR-145, which inhibit the expression of several 
stem-cell factors including OCT4, KLF4, LIN28A, and SOX2.10 
Additionally, it has been shown that tristetraprolin induced by 
p53 in cancer cells increases the level of let-7, a known tumor 
suppressor, via downregulation of LIN28A.11 Blockade of the 
processing of various microRNAs, including let-7, has been sug-
gested as one of the pathogenetic mechanisms of LIN28A in hu-
man carcinogenesis.12-15 In addition, LIN28A has been reported 
to suppress many other factors including OCT4, SOX2, and 
NANOG, which are involved in reprogramming human somatic 
cells, by post-transcriptional regulation.16,17
Expression of LIN28A has been identified in various human 
cancers, including breast cancer,18 ovarian cancer,19 hepatocel-
lular carcinoma,9 and colorectal cancer.20 As for gastric can-
cer, one study from China showed that positive expression of 
LIN28A was correlated with poor overall survival.21 However, 
expression of LIN28A was found to be more common in cor-
responding normal tissue than in gastric cancer tissue in that 
study. In addition, the study did not fully adjust for TNM stages 
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in the survival analysis. Therefore, we cannot be certain wheth-
er LIN28A expression is a poor prognostic factor in patients 
with gastric cancer. In the current study, we aimed to evaluate 
clinicopathological characteristics according to the expression 
of LIN28A by using a large number of gastric cancer tissue 
samples.
MATERIALS AND METHODS
1. Study design and patient population
In order to evaluate the relationship between the clinicopath-
ological characteristics of gastric cancers and the expression 
of LIN28A, we performed immunohistochemical (IHC) staining 
for LIN28A using tissue microarrays (TMAs). The TMAs were 
constructed from 288 pairs of gastric cancer tissue samples and 
corresponding normal tissues that were obtained from patients 
who had undergone curative surgery for gastric cancer at the 
same center between April 2001 and December 2003. We col-
lected the following data from the patients’ medical records: de-
mographic information, tumor location, histology, TNM staging, 
and overall survival duration. This study was approved by the 
Institutional Review Board of Severance Hospital.
2. Tissue microarray construction
The TMAs were constructed as previously described.22 On 
hematoxylin and eosin-stained slides of tumors, a representa-
tive area was selected, and the corresponding spot was marked 
on the surface of the paraffin block. Using a biopsy needle, the 
selected area was punched out, and a 2-mm tissue core was 
placed into an 8×6 recipient block. Gastric cancer tissues and 
corresponding normal tissues were then extracted. Each tissue 
core was assigned a unique TMA location number that was 
linked to a database containing other clinicopathological data.
3. Immunohistochemistry
IHC analyses were performed on formalin-fixed, paraffin-
embedded tissues, using the TMA. The slides were deparaf-
finized in xylene and rehydrated through an ethanol gradient. 
Endogenous peroxidase was blocked with 3% H2O2 for 10 
minutes. The slides were immersed in 10 mM citrate buffer (pH 
6.0) and heated for 10 minutes for antigen retrieval. Nonspecific 
binding was blocked by preincubation with a protein blocking 
agent (Immunotech Laboratories Inc., Monrovia, CA, USA), and 
the slides were incubated at room temperature for 1 hour with 
antibody against LIN28A (rabbit polyclonal, 1:500; Abcam, 
Cambridge, MA, USA). The samples were washed three times 
with phosphate-buffered saline (PBS) and then incubated with 
secondary antibodies for 30 minutes. After an additional three 
washes in PBS, the slides were incubated with the streptavidin-
horseradish peroxidase complex (Dako, Glostrup, Denmark) for 
30 minutes. The slides were visualized with diaminobenzidine 
(Dako) and then counterstained with hematoxylin. The expres-
sion of the antibodies was assessed semiquantitatively by esti-
mating the percentage of tumor cells with positive cytoplasm 
staining among the entire population of tumor cells. All slides 
were examined and scored independently by two experienced 
investigators to avoid subjective biases. Each slide was exam-
ined in its entirety under a light microscope, and a proportion 
score was initially assigned, which represented the estimated 
proportion of positive tumor cells (0, none; 1, 0% to 10%; 2, 
10% to 50%; and 3, 50% to 100%). Next, an intensity score was 
assigned, which represented the average intensity of the positive 
tumor cells (0, none; 1, weak; 2, intermediate; and 3, strong). 
The proportion and intensity scores were then multiplied to 
obtain a total score, which ranged from 0 to 9, and high expres-
sion of LIN28A was defined as a total score ≥2.21
4. Statistical analysis
Statistical tests used to compare the measured results included 
the t-test, Mann-Whitney U test, chi-square test, and Fisher ex-
act test. The Kaplan-Meier method and log-rank test were used 
for survival analysis. In addition, the Cox proportional hazards 
model was used to adjust for possible confounding variables 
including TNM stage. A value of p less than 0.05 was regarded 
as a statistically significant difference for comparisons between 
groups. All statistical procedures were conducted using the 
statistical software SPSS for Windows version 18.0 (SPSS Inc., 
Chicago, IL, USA) with the exception of the survival analysis, 
which was performed using R version 2.15.3 (R Foundation for 
Statistical Computing, Vienna, Austria).
RESULTS
1. Comparison of LIN28A expression between cancer  
tissues and corresponding normal tissues 
IHC staining was performed on 288 pairs of normal and can-
cer tissue samples to analyze the difference in LIN28A expres-
sion. The mean IHC staining score was higher in the normal tis-
sues than in the cancer tissues (normal vs cancer [mean±standard 
deviation], 2.0±1.6 vs 1.1±1.5; p<0.001). The proportion of 
tissues with LIN28A expression was higher in the normal tissues 
than in the cancer tissues (normal vs cancer, 63.5% vs 35.4%; 
p<0.001).
2. LIN28A expression and clinicopathological characteristics 
of gastric cancer
The clinicopathological characteristics of the enrolled patients 
according to the LIN28A expression of cancer tissues on IHC 
staining are shown in Table 1. High expression of LIN28A was 
shown in 102 of 288 patients (35.4%). The mean patient age 
and the proportion of men did not differ between the groups 
(p=0.469 and p=0.217, respectively). Neither tumor location nor 
histology differed between the groups (p=0.148 and p=0.827, 
respectively). In addition, T, N, and TNM stages did not differ 
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between the groups (p=0.284, p=0.375, and p=0.725, respec-
tively).
3. Survival analysis according to LIN28A expression
Kaplan-Meier plots were used to illustrate overall survival ac-
cording to the expression of LIN28A (Fig. 1). The median follow-
up durations were 69.4 months (interquartile range [IQR], 60.6 
to 77.4 months) and 66.9 months (IQR, 40.8 to 76.7 months) in 
the low and high expression groups, respectively (p=0.158). The 
5-year overall survival was 75.3% (95% confidence interval [CI], 
69.3% to 81.7%) in the low expression group and 71.6% (95% 
CI, 63.3% to 80.9%) in the high expression group. The duration 
of overall survival did not differ between the groups (p=0.405).
A Cox proportional hazards model showed that high LIN28A 
expression was not an independently associated factor for death 
after adjusting for TNM stage (hazard ratio, 1.191; 95% CI, 0.758 
to 1.872) (Table 2).
DISCUSSION
LIN28A has been considered an oncogene in the development 
of various human cancers.9,18-20 One of the possible mechanisms 
of LIN28A as an oncogene is downregulation of the let-7 fam-
ily, well-known microRNAs that function as tumor suppres-
sors.12-14 Under this hypothesis, Xu et al.21 performed a study 
on the expression of LIN28A in gastric cancer patients via real-
Table 1. Clinicopathological Characteristics according to LIN28A Expression via Immunohistochemical Staining
Variable
Low expression on IHC staining  
(IHC staining score <2) (n=186)
High expression on IHC staining  
(IHC staining score ≥2) (n=102)
p-value
Age, yr 56.2±12.1 55.1±12.8 0.469
Sex 0.217
   Male 116 (62.4) 56 (54.9)
   Female 70 (37.6) 46 (45.1)
Location 0.148
   Upper third 34 (18.3) 29 (28.4)
   Middle third 34 (18.3) 14 (13.7)
   Lower third 115 (61.8) 59 (57.8)
   Anastomosis site 3 (1.6) 0 
Histology 0.827
   AWD or AMD 45 (24.2) 28 (27.5)
   APD or SRC 129 (69.4) 68 (66.7)
   Others* 12 (6.5) 6 (5.9)
T stage 0.284
   pT1 3 (1.6) 0 
   pT2 31 (16.7) 25 (24.5)
   pT3 65 (34.9) 34 (33.3)
   pT4 87 (46.8) 43 (42.2)
N stage 0.375
   pN0 74 (39.8) 36 (35.3)
   pN1 54 (29.0) 25 (24.5)
   pN2 32 (17.2) 26 (25.5)
   pN3 26 (14.0) 15 (14.7)
TNM stage 0.725
   IIa 59 (31.7) 30 (29.4)
   IIb 65 (34.9) 34 (33.3)
   IIIa 28 (15.1) 19 (18.6)
   IIIb 14 (7.5) 11 (10.8)
   IIIc 20 (10.8) 8 (7.8)
Data are presented as mean±SD or number (%).
IHC, immunohistochemical; AWD, adenocarcinoma well differentiated; AMD, adenocarcinoma moderated differentiated; APD, adenocarcinoma 
poorly differentiated; SRC, signet ring cell carcinoma.
*This category included mucinous adenocarcinoma, lymphoepithelioma-like carcinoma, and glandular endocrine carcinoma.
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time polymerase chain reaction analysis and IHC staining. In 
their study, however, the expression level of LIN28A in normal 
tissues was higher than that in cancer tissues (normal vs cancer, 
62.8% vs 46.0%). Although it was shown that LIN28A expres-
sion was independently associated with poor overall survival, 
the authors could not clearly explain how LIN28A expression 
affected the overall survival of patients with gastric cancer. We 
questioned whether the expression of LIN28A really has a nega-
tive influence on overall survival in patients with gastric cancer.
In our study, similar proportions of cancer tissues and cor-
responding normal tissues showed expression of LIN28A on IHC 
staining (normal vs cancer, 63.5% vs 35.4%) compared to the 
results of Xu et al.21 However, no associated clinicopathological 
factor for the high LIN28A expression in gastric cancers was 
identified. Unlike Xu et al.,21 we classified gastric cancers into 
four or five groups according to T stage (pT1, pT2, pT3, and 
pT4), N stage (pN0, pN1, pN2, and pN3), and TNM stage (IIa, IIb, 
IIIa, IIIb, and IIIc). These detailed classifications were selected to 
stratify the gastric cancers more accurately for survival analy-
sis. As a result, we showed that LIN28A expression was not an 
independently associated factor for overall survival. The expres-
sion of LIN28A seemed to have no distinct role in predicting 
clinicopathological characteristics including survival outcomes 
in patients with gastric cancer.
Our results, which are in conflict with the usual expectation 
that LIN28A may have a role as an oncogene, are likely due to 
the various roles of LIN28A aside from repressing let-7. First, 
overexpression of LIN28A induces the expression of several 
transcription factors that are involved in early embryonic-cell 
fate decisions. Moreover, LIN28A functions independently of 
let-7.23 Second, LIN28A directly regulates various metabolisms 
including oxidative phosphorylation or glucose metabolism.24,25 
Third, LIN28A may facilitate the global translational suppres-
sion of endoplasmic reticulum-associated mRNAs in undifferen-
tiated stem cells.26 We believe that LIN28A may have a role not 
only in gastric cancer cells but also in normal gastric cells. In 
addition, the heterogeneity of gastric cancers could contribute 
to the discrepancy between the results of Xu et al.’s study and 
ours.27,28 A better understanding of the molecular biology of 
gastric cancers and appropriate selection of the patient popula-
tion might be necessary to clarify the role of LIN28A in gastric 
carcinogenesis.
Although this was the largest study to date that evaluated 
clinicopathological characteristics according to the expres-
sion of LIN28A in patients with gastric cancer, it has several 
limitations. First, we did not assess the lesion characteristics 
according to well-known associated factors for gastric cancer, 
including Helicobacter pylori infection status and family history 
of gastric cancer. Unfortunately, H. pylori infection status and 
family history were unavailable in our gastric cancer cohort for 
TMAs. Second, various associated factors for LIN28A including 
p53, Ki-67, miR-34a, miR-145, and let-7, were not analyzed in 
the study. Evaluating these factors might support the negative 
results of our study in patients with gastric cancer. The lack 
of an analysis of LIN28B was another limitation of the study. 
Although the study was performed to validate the results of the 
previous study,21 expression of LIN28B should be investigated 
to better understand LIN28 in patients with gastric cancer.29,30 
Despite these limitations, our data may form the basis of a 
system that can be used to understand the clinicopathological 
characteristics based on LIN28A expression. 
The expression of LIN28A seemed to have no distinct role in 
predicting clinicopathological characteristics in gastric cancer. 
Additionally, LIN28A expression was not an independently asso-
ciated factor for overall survival in patients with gastric cancer.
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Fig. 1. Kaplan-Meier plots for the overall survival rate according to 
LIN28A expression. The median follow-up durations of the low- and 
high-expression groups were 69.4 months (interquartile range [IQR], 
60.6 to 77.4 months) and 66.9 months (IQR, 40.8 to 76.7 months), 
respectively. 
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Table 2. Cox Proportional Hazards Model for Predicting Death
Variable Hazard ratio (95% CI) p-value
TNM stage
   IIa 1
   IIb 1.361 (0.672–2.757)  0.392
   IIIa 3.302 (1.608–6.779)  0.001
   IIIb 5.172 (2.340–11.434) <0.001
   IIIc 7.897 (3.826–16.296) <0.001
High LIN28A expression 1.191 (0.758–1.872)  0.448
CI, confidence interval. 
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